~18 spots leftby Apr 2026

Optimizing Pulsatility During Cardiopulmonary Bypass

NJ
Overseen byNathan J Clendenen, MD, MS
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of Colorado, Denver
No Placebo Group

Trial Summary

What is the purpose of this trial?

Cardiopulmonary bypass during cardiac surgery provides blood flow to the body during surgery but has adverse effects on different organs. Blood flow during cardiopulmonary bypass may be pulsatile or non-pulsatile, which may impact normal organ function after surgery. The study will collect data on the type of cardiopulmonary bypass used during surgery and organ function to determine if there is an association between the type of bypass and organ function.

Research Team

NJ

Nathan J Clendenen, MD, MS

Principal Investigator

University of Colorado Denver | Anschutz

Eligibility Criteria

Inclusion Criteria

Age 50 to 70
Able to provide informed consent
Scheduled for elective cardiac surgery with cardiopulmonary bypass

Treatment Details

Interventions

  • Cardiopulmonary Bypass (Procedure)

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+
Aviva Abosch profile image

Aviva Abosch

University of Colorado, Denver

Chief Medical Officer since 2019

MD

Uday B. Kompella profile image

Uday B. Kompella

University of Colorado, Denver

Chief Executive Officer since 2015

PhD in Pharmaceutical Sciences

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+
Dr. Gary H. Gibbons profile image

Dr. Gary H. Gibbons

National Heart, Lung, and Blood Institute (NHLBI)

Chief Executive Officer since 2012

MD from Harvard Medical School

Dr. James P. Kiley profile image

Dr. James P. Kiley

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer since 2011

MD from University of California, San Francisco